New treatments to prevent tooth decay in children
Novel Biofilm Inhibitors of Oral Streptococci
This study is looking at a new way to help prevent tooth decay in kids by using tiny particles called cerium oxide nanoparticles, which could be a safer option than traditional silver treatments, and it aims to find a long-lasting solution that can help children who might not see the dentist often.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10640889 on NIH RePORTER |
What this research studies
This research investigates the use of cerium oxide nanoparticles as a novel way to inhibit harmful bacteria that cause tooth decay in children. By focusing on non-bactericidal methods, the study aims to provide a safer alternative to traditional silver treatments, which can have undesirable side effects. The approach involves testing these nanoparticles in laboratory settings to assess their effectiveness in preventing biofilm formation by oral Streptococci, the bacteria responsible for dental caries. The goal is to develop a long-lasting preventive treatment that can be used, especially for children who may not have regular access to dental care.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years who are at risk for dental caries, particularly those from low socioeconomic backgrounds.
Not a fit: Patients who do not have dental caries or are not within the pediatric age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective preventive treatments for dental caries in children, improving their oral health and overall well-being.
How similar studies have performed: Other research has shown promising results with similar nanoparticle approaches in inhibiting bacterial growth, suggesting potential for success in this novel application.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Pesavento, Russell P — University of Illinois at Chicago
- Study coordinator: Pesavento, Russell P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.